US-based Precision Diabetes, Inc. and South Korea's DxGen Corp. have entered in an exclusive agreement in the US to launch Epithod AutoDx, a fully-automatic point-of-care (POC) analyser that measures a comprehensive profile of diabetes tests.  The initial test menu will begin with hemoglobin A1c (A1C), C-reactive protein, and urinary albumin, with additional diabetes tests to be added in the near future.

Epithod AutoDx is a small analyzer with a very user-friendly design and easy operation, making it uniquely suitable for point-of-care settings such as physician offices, smaller laboratories, outpatient clinics, and hospitals.  By providing a suite of diabetes tests in these settings, clinicians will be able to provide "real-time," actionable test results to patients, rather than waiting for several days for standard laboratory test results.

The diabetes POC testing market continues to expand rapidly as the diabetic epidemic continues unabated.  The global POC A1C testing market alone is estimated to be $500 million and is expected to grow to $680 million by 2023. The Epithod AutoDx is well positioned to become a dominant player in this market as the diabetes test menu continues to expand.

"The COVID-19 pandemic has accelerated on-site testing worldwide, and Epithod AutoDx can measure multiple diabetes tests on one point-of-care analyzer, providing rapid results that enable clinicians to make faster clinical decisions," said Jinwoo Lee of DxGen.  "The strategic partnership in the United States between the two companies creates a powerful combination to help people with prediabetes and diabetes."